He posits that even costs of generics would go up as CFCs become scarcer.Gross disagrees, saying that the inhaler shortage and the closure of CFC manufacturing plants are a result of the ban.

• 他推测，随著氟氯碳化物越来越少，连非专利药的成本都会增加，但葛罗斯并不苟同，他表示，吸入器之短缺和氟氯碳化物制造厂倒闭，是该禁令所致。